Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observational Study Evaluating the Safety and Efficacy of the Treatment With Biphasic Insulin Aspart (NovoMix 30 FlexPen) [Insulin-aspart/insulin-protamine-aspart] in the Treatment of Type 2 Diabetics After Failing on Basal/ Intermediate Mono or Combination Therapy.

Trial Profile

An Observational Study Evaluating the Safety and Efficacy of the Treatment With Biphasic Insulin Aspart (NovoMix 30 FlexPen) [Insulin-aspart/insulin-protamine-aspart] in the Treatment of Type 2 Diabetics After Failing on Basal/ Intermediate Mono or Combination Therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Mar 2016

At a glance

  • Drugs Insulin aspart/insulin protamine aspart (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 17 Dec 2009 Actual end date changed from Jun 2009 to May 2009 as reported by ClinicalTrials.gov.
    • 08 Jul 2009 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top